Related Experiment Video
Updated: Oct 6, 2025

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Published on: May 30, 2025
A Clinical Framework for Evaluating Cannabis Product Quality and Safety
Caroline A MacCallum1,2, Lindsay A Lo3, Carly A Pistawka4
1Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract:
Increase in medical cannabis use, along with available products, warrants the need for clinicians to be knowledgeable in evaluating the quality of any cannabis product presented in clinical practice. Determining whether a product is regulated within the region is key in assessing overall quality and safety. Regulated products are held to a higher standard including independent testing, contamination mitigation, and concentration limits. Here, we present a clinical framework in evaluating cannabis products to ascertain the quality and regulation level of the product. Evaluation includes assessing the source company, reviewing product details (e.g., type, cannabinoid content, and labeling), and assessing quality control variables such as manufacturing and decontamination processes. The quality of products patients use is an important part of mitigating cannabis-related harms, especially in medically vulnerable patients. Currently, there is a great need to implement widespread standardization and regulations to ensure product quality and safety.
Related Concept Videos
Drug Regulation
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Preclinical Development: Overview
Clinical Trials: Overview
Drug Control Governance: Regulatory Bodies and Their Impact

